(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/222094 A1

(51) International Patent Classification:
A61K 35/761 (2015.01) *A61K 48/00* (2006.01)
A61K 38/47 (2006.01)

(21) International Application Number:
PCT/US2021/029146

(22) International Filing Date:
26 April 2021 (26.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/016,207 27 April 2020 (27.04.2020) US
63/114,195 16 November 2020 (16.11.2020) US

(71) Applicant: **4D MOLECULAR THERAPEUTICS INC.** [US/US]; 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US).

(72) Inventors: **KIRN, David, H.**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). **KOTTERMAN, Melissa**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). **FRANCIS, Peter**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). **SCHAFFER, David**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). **SZYMANSKI, Paul**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US). **WHITTLESEY, Kevin**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, CA 94608 (US).

(74) Agent: **CABRAL, Christopher, M.** et al.; Much Shelist PC, 191 N. Wacker Drive, Suite 1800, Chicago, IL 60606-1615 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

(54) Title: CODON OPTIMIZED GLA GENES AND USES THEREOF

Figure 1



(57) Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.

WO 2021/222094 A1

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*